NCT05542576View on ClinicalTrials.gov

Study of AMDX-2011P as a Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

March 15, 2023

Study Completion Date

March 15, 2023

Conditions
Parkinson DiseaseAmyotrophic Lateral Sclerosis
Interventions
DRUG

AMDX2011P

AMDX2011P single bolus injection intravenous for diagnostic review

Trial Locations (2)

91107

Brittany NIcholl, Pasadena

92663

Eye Research Foundation, Newport Beach

All Listed Sponsors
lead

Amydis Inc.

INDUSTRY